153 related articles for article (PubMed ID: 38550598)
1. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Huang JQ; Liang HW; Liu Y; Chen L; Pei S; Yu BB; Pan XB
Front Immunol; 2024; 15():1355198. PubMed ID: 38550598
[TBL] [Abstract][Full Text] [Related]
2. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers.
Chen F; Luo H; Xing L; Liang N; Xie J; Zhang J
Thorac Cancer; 2018 Jan; 9(1):59-65. PubMed ID: 29024498
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
Chen CY; Li CC; Chien CR
World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409
[TBL] [Abstract][Full Text] [Related]
6. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial.
Liu Y; Zheng Z; Li M; Zhang Y; Zhao F; Gong H; Lin H; Huang W; Chen X; Xu Z; Li X; Liu W; Cui Y; Zheng A; Li B
Int J Cancer; 2022 Aug; 151(4):607-615. PubMed ID: 35419831
[TBL] [Abstract][Full Text] [Related]
7. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.
Hu L; Kong Z; Meng Q; Wang J; Zhou M; Yu J; Jiang X
Med Sci Monit; 2020 Nov; 26():e927221. PubMed ID: 33243967
[TBL] [Abstract][Full Text] [Related]
8. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Park S; Oh D; Choi YL; Chi SA; Kim K; Ahn MJ; Sun JM
Cancer; 2022 Jun; 128(11):2148-2158. PubMed ID: 35319779
[TBL] [Abstract][Full Text] [Related]
10. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.
Shi Z; Zhu X; Ke S; Qiu H; Cai G; Zhangcai Y; Chen Y
Radiother Oncol; 2021 Nov; 164():236-244. PubMed ID: 34627936
[TBL] [Abstract][Full Text] [Related]
11. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.
Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B
Front Immunol; 2023; 14():1193394. PubMed ID: 37325650
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
Ren X; Wang L; Han C; Ren L
Radiother Oncol; 2018 Nov; 129(2):293-299. PubMed ID: 30270099
[TBL] [Abstract][Full Text] [Related]
13. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC.
Wang G; Beeraka NM; Xiao W; Zhang Y; Xue N; Chen G; Liu J; Liu Y
Technol Cancer Res Treat; 2022; 21():15330338221080939. PubMed ID: 35235470
[No Abstract] [Full Text] [Related]
14. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
[TBL] [Abstract][Full Text] [Related]
15. Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?
Zhang P; Xi M; Zhao L; Shen JX; Li QQ; He LR; Liu SL; Liu MZ
PLoS One; 2014; 9(8):e105270. PubMed ID: 25133495
[TBL] [Abstract][Full Text] [Related]
16. Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.
Zhou XL; Zhu WG; Zhu ZJ; Wang WW; Deng X; Tao WJ; Ji FZ; Tong YS
Oncologist; 2019 Aug; 24(8):e677-e686. PubMed ID: 31040254
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Clinical Outcomes of Esophagectomy and Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.
Lee MH; Park MI; Lee JW; Jung K; Kim JH; Kim SE; Moon W; Park SJ
Korean J Gastroenterol; 2024 Mar; 83(3):102-110. PubMed ID: 38522853
[TBL] [Abstract][Full Text] [Related]
18. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
Front Immunol; 2022; 13():970534. PubMed ID: 36275724
[TBL] [Abstract][Full Text] [Related]
19. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.
Chen Y; Guo L; Cheng X; Wang J; Zhang Y; Wang Y; Ke S; Shi W
Radiother Oncol; 2018 Oct; 129(1):154-160. PubMed ID: 29122362
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
Shi Z; Zhu X; Ruan C; Wei G; Li J; Qiu H; Gao L; Cai G; Zhangcai Y; Li B; Wang J; Gong Y; Chen J; Zhao W; Wu Y; Ke S; Chen Y
JAMA Netw Open; 2022 Dec; 5(12):e2244619. PubMed ID: 36454568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]